Cargando…

The Effect of Low-Dose Marine n-3 Fatty Acids on Plasma Levels of sCD36 in Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial

CD36 is a scavenger receptor involved in lipid uptake and inflammation. Recently, non-cell-bound CD36 (sCD36) was identified in plasma and suggested to be a marker of lipid accumulation in the vessel wall. Marine n-3 polyunsaturated fatty acids (PUFA) may have cardioprotective effects. This study ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Venø, Stine Krogh, Nielsen, Michael René Skjelbo, Lundbye-Christensen, Søren, Schmidt, Erik Berg, Handberg, Aase
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806470/
https://www.ncbi.nlm.nih.gov/pubmed/23999661
http://dx.doi.org/10.3390/md11093324
_version_ 1782288385325400064
author Venø, Stine Krogh
Nielsen, Michael René Skjelbo
Lundbye-Christensen, Søren
Schmidt, Erik Berg
Handberg, Aase
author_facet Venø, Stine Krogh
Nielsen, Michael René Skjelbo
Lundbye-Christensen, Søren
Schmidt, Erik Berg
Handberg, Aase
author_sort Venø, Stine Krogh
collection PubMed
description CD36 is a scavenger receptor involved in lipid uptake and inflammation. Recently, non-cell-bound CD36 (sCD36) was identified in plasma and suggested to be a marker of lipid accumulation in the vessel wall. Marine n-3 polyunsaturated fatty acids (PUFA) may have cardioprotective effects. This study evaluated the effect of marine n-3 PUFA on sCD36 levels in overweight subjects. Fifty overweight subjects were randomized to 1.1 g of n-3 PUFA or 2 g of olive oil daily for six weeks. Neutrophils were isolated at baseline and after six weeks of treatment while an adipose tissue biopsy was obtained at baseline. The content of n-3 PUFA in adipose tissue and neutrophils was analyzed by gas chromatography, while plasma levels of sCD36 were determined using an enzyme-linked immunosorbent assay (ELISA). After six weeks of supplement plasma sCD36 did not differ between supplements (P = 0.18). There was no significant correlation between plasma sCD36 levels and n-3 PUFA in neutrophils at baseline (r = −0.02, P = 0.88), after six weeks supplement (r = −0.03, P = 0.85) or in adipose tissue (r = 0.14, P = 0.34). This study therefore does not provide evidence for a cardioprotective effect of n-3 PUFA acting through a CD36-dependent mechanism.
format Online
Article
Text
id pubmed-3806470
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-38064702013-10-23 The Effect of Low-Dose Marine n-3 Fatty Acids on Plasma Levels of sCD36 in Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial Venø, Stine Krogh Nielsen, Michael René Skjelbo Lundbye-Christensen, Søren Schmidt, Erik Berg Handberg, Aase Mar Drugs Article CD36 is a scavenger receptor involved in lipid uptake and inflammation. Recently, non-cell-bound CD36 (sCD36) was identified in plasma and suggested to be a marker of lipid accumulation in the vessel wall. Marine n-3 polyunsaturated fatty acids (PUFA) may have cardioprotective effects. This study evaluated the effect of marine n-3 PUFA on sCD36 levels in overweight subjects. Fifty overweight subjects were randomized to 1.1 g of n-3 PUFA or 2 g of olive oil daily for six weeks. Neutrophils were isolated at baseline and after six weeks of treatment while an adipose tissue biopsy was obtained at baseline. The content of n-3 PUFA in adipose tissue and neutrophils was analyzed by gas chromatography, while plasma levels of sCD36 were determined using an enzyme-linked immunosorbent assay (ELISA). After six weeks of supplement plasma sCD36 did not differ between supplements (P = 0.18). There was no significant correlation between plasma sCD36 levels and n-3 PUFA in neutrophils at baseline (r = −0.02, P = 0.88), after six weeks supplement (r = −0.03, P = 0.85) or in adipose tissue (r = 0.14, P = 0.34). This study therefore does not provide evidence for a cardioprotective effect of n-3 PUFA acting through a CD36-dependent mechanism. MDPI 2013-08-30 /pmc/articles/PMC3806470/ /pubmed/23999661 http://dx.doi.org/10.3390/md11093324 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Venø, Stine Krogh
Nielsen, Michael René Skjelbo
Lundbye-Christensen, Søren
Schmidt, Erik Berg
Handberg, Aase
The Effect of Low-Dose Marine n-3 Fatty Acids on Plasma Levels of sCD36 in Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial
title The Effect of Low-Dose Marine n-3 Fatty Acids on Plasma Levels of sCD36 in Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial
title_full The Effect of Low-Dose Marine n-3 Fatty Acids on Plasma Levels of sCD36 in Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial
title_fullStr The Effect of Low-Dose Marine n-3 Fatty Acids on Plasma Levels of sCD36 in Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial
title_full_unstemmed The Effect of Low-Dose Marine n-3 Fatty Acids on Plasma Levels of sCD36 in Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial
title_short The Effect of Low-Dose Marine n-3 Fatty Acids on Plasma Levels of sCD36 in Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial
title_sort effect of low-dose marine n-3 fatty acids on plasma levels of scd36 in overweight subjects: a randomized, double-blind, placebo-controlled trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806470/
https://www.ncbi.nlm.nih.gov/pubmed/23999661
http://dx.doi.org/10.3390/md11093324
work_keys_str_mv AT venøstinekrogh theeffectoflowdosemarinen3fattyacidsonplasmalevelsofscd36inoverweightsubjectsarandomizeddoubleblindplacebocontrolledtrial
AT nielsenmichaelreneskjelbo theeffectoflowdosemarinen3fattyacidsonplasmalevelsofscd36inoverweightsubjectsarandomizeddoubleblindplacebocontrolledtrial
AT lundbyechristensensøren theeffectoflowdosemarinen3fattyacidsonplasmalevelsofscd36inoverweightsubjectsarandomizeddoubleblindplacebocontrolledtrial
AT schmidterikberg theeffectoflowdosemarinen3fattyacidsonplasmalevelsofscd36inoverweightsubjectsarandomizeddoubleblindplacebocontrolledtrial
AT handbergaase theeffectoflowdosemarinen3fattyacidsonplasmalevelsofscd36inoverweightsubjectsarandomizeddoubleblindplacebocontrolledtrial
AT venøstinekrogh effectoflowdosemarinen3fattyacidsonplasmalevelsofscd36inoverweightsubjectsarandomizeddoubleblindplacebocontrolledtrial
AT nielsenmichaelreneskjelbo effectoflowdosemarinen3fattyacidsonplasmalevelsofscd36inoverweightsubjectsarandomizeddoubleblindplacebocontrolledtrial
AT lundbyechristensensøren effectoflowdosemarinen3fattyacidsonplasmalevelsofscd36inoverweightsubjectsarandomizeddoubleblindplacebocontrolledtrial
AT schmidterikberg effectoflowdosemarinen3fattyacidsonplasmalevelsofscd36inoverweightsubjectsarandomizeddoubleblindplacebocontrolledtrial
AT handbergaase effectoflowdosemarinen3fattyacidsonplasmalevelsofscd36inoverweightsubjectsarandomizeddoubleblindplacebocontrolledtrial